Clinical trials
Resistance clinical trials
Below are recruiting resistance clinical trials, each written for real people, not researchers. We’re tracking 1,200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07284667RecruitingPhase 2
A new medicine for depression that hasn't improved with other treatments
This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.
Birmingham, AlabamaAges 18–65 - NCT06762054Recruiting
Better management for dolutegravir-resistant HIV
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
KisumuAges 1 year+ - NCT06747507RecruitingPhase 3
Ndovu study: best HIV treatment for drug resistance
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
KisumuAges 3 years+ - NCT06774547Recruiting
Early jumping exercises for leg tendon pain
This study tests whether adding jumping exercises early helps people with long-lasting leg tendon pain recover faster.
AalborgAges 18–50 - NCT06666127Enrolling by invitation
Muscle force and growth study
This study looks at how the force of your muscle contractions at different lengths affects muscle growth and strength. You will do leg exercises on a special machine to see how your muscles respond.
Vancouver, British ColumbiaAges 19–30 - NCT06677749Recruiting
Muscle response to eccentric exercise trial
This trial studies how your muscles respond to a specific type of exercise that focuses on lengthening movements, like lowering a weight. It may help us understand how exercise keeps muscles healthy.
Winnipeg, ManitobaAges 18–35 - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT06193668Recruiting
Overfeeding and fat tissue stimulation study
This trial looks at how overfeeding affects fat tissue in healthy, inactive young adults. You may help researchers understand weight gain and metabolism.
Düsseldorf, North Rhine-WestphaliaAges 18–40 - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT06330012Recruiting
Understanding resistance to T-Dxd in HER2+ breast cancer
This study looks at why some HER2-positive breast cancer patients stop responding to the drug T-Dxd (trastuzumab deruxtecan). It aims to find out how resistance develops, which may help improve future treatments.
SeoulAges Any age - NCT05942001RecruitingPhase 1
Testing an investigational drug for advanced prostate cancer
This Phase 1 trial tests HRS-5041 in people with metastatic castration-resistant prostate cancer (prostate cancer that keeps growing despite lower testosterone). It aims to see if the drug can be given safely and whether it may help control the cancer after prior standard treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05972876Recruiting
Blood-flow restriction rehab after ACL surgery
This trial looks at how well your ACL graft (the repaired tissue) heals after ACL reconstruction when you use a specific rehab method called blood-flow restriction training. It may help your care team understand whether this rehab approach leads to better healing and function.
Sittard, LimburgAges 18–65 - NCT06014528RecruitingPhase 2
IN10018 plus liposomal doxorubicin for platinum-resistant ovarian cancer
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
BeijingAges 18 years+ - NCT06126731RecruitingPhase 1/Phase 2
Antibiotics plus enzalutamide for advanced prostate cancer
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
BellinzonaAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT05843604Recruiting
Brain and thinking tests to study OCD treatment resistance
This study looks at brain and thinking (cognitive) markers to understand why some people with obsessive-compulsive disorder (OCD) don’t respond as well to treatment. If you have OCD, you may be asked to take tests and follow the study rules to help researchers better predict treatment resistance.
PoitiersAges 18–70 - NCT05881265RecruitingPhase 2
Chidamide plus venetoclax for hard-to-treat APL
This trial studies chidamide and venetoclax in people with a specific type of acute promyelocytic leukemia (APL) that has not responded to standard treatment with all-trans retinoic acid (RA) plus arsenic. It may help by testing a new combination for cases in “non-remission” status.
Huai'an, JiangsuAges 16–70 - NCT05563558RecruitingPhase 2
Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
MadridAges 18 years+ - NCT05331937RecruitingPhase 3
TMS plus exposure therapy for severe OCD that won’t improve
This trial studies whether TMS (a brain stimulation treatment) can help people with severe OCD who have not responded well to exposure therapy. It combines brain stimulation with intensive exposure therapy to reduce obsessions and compulsions.
Amsterdam, North HollandAges 18 years+ - NCT05381194RecruitingPhase 4
Tested medicines for drug-resistant lung tuberculosis
This trial studies a specific drug combination (BPaLM) for adults with drug-resistant pulmonary (lung) tuberculosis. If you qualify, the goal is to see whether this treatment is effective and safe for your type of infection.
Seoul, Songpa-guAges 19 years+ - NCT05551507RecruitingPhase 1/Phase 2
Test drug IN10018 plus chemotherapy for platinum-resistant ovarian cancer
This trial tests IN10018 together with standard chemotherapy in people with high-grade serous ovarian (or related) cancer that has come back or progressed soon after platinum treatment. The goal is to see if adding IN10018 can improve cancer control and safety.
AnyangAges 18 years+ - NCT06513624RecruitingPhase 1
ETC-159 plus pembrolizumab for advanced ovarian cancer
This trial tests a new combination of two drugs—ETC-159 (a pill that targets a specific growth pathway) and pembrolizumab (an immunotherapy)—for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Singapore, SingaporeAges 21–99 - NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT03522064RecruitingPhase 2
HRD-positive advanced prostate cancer trial with androgen therapy and chemo
This Phase 2 study tests whether blocking male hormones (androgen therapy) plus the chemotherapy drug carboplatin can shrink advanced prostate cancer in men with specific DNA repair problems. It is for cases where prostate-specific antigen (PSA) is rising even though testosterone is already kept very low.
Sydney, New South WalesAges 18 years+
Hear when a new Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistance?
- Yes. Clin2 currently lists 1,200 recruiting resistance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.